What we do

Our lab focuses on understanding how PDAC patient heterogeneity is regulated and how the complex interactions with and within the tumor microenvironment impact disease outcome and treatment response. To address these questions, we maintains active collaborations with clinical partners and makes use of primary human in vitro and in vivo models, state-of-the-art omics technologies, and bioinformatic analyses of public and self-generated patient data. Our group aims at understanding pancreatic cancer tumors as a whole with the goal of defining new therapies that translate into a measurable benefit in PDAC patients.